Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia

A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia

To demonstrate the effect of JTT-705 doses from 300 mg to 900 mg on the elevation of HDL-C and on the inhibition of CETP activity versus placebo, in patients presenting with mild dyslipidaemia. These objectives will be tested after 4 weeks of treatment.

Inclusion Criteria:

• Patients with of Type II hyperlipidaemia

• Patients having lipid values as indicated below:

  • HDL-C < 1.6 mmol/l
  • TG < 4.5 mmol/l

• Male and females between 18 and 65 years old (If female must be post-menopausal, or pre-menopausal and surgically sterile or using an acceptable form of contraception)

Exclusion Criteria:

• Body Mass Index (BMI) > 35 kg/m²
• Pregnant, breast feeding, or woman with child bearing potential without an effective method of contraception
• Concomitant use of medications identified in the protocol